IMNM vs. EWTX, AMRX, KYMR, JANX, ARWR, NAMS, PTGX, VERA, CGON, and HRMY
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Edgewise Therapeutics (EWTX), Amneal Pharmaceuticals (AMRX), Kymera Therapeutics (KYMR), Janux Therapeutics (JANX), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), CG Oncology (CGON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.
Immunome vs.
Edgewise Therapeutics (NASDAQ:EWTX) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.
Edgewise Therapeutics has higher earnings, but lower revenue than Immunome. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Edgewise Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Edgewise Therapeutics' return on equity of -26.83% beat Immunome's return on equity.
Edgewise Therapeutics received 2 more outperform votes than Immunome when rated by MarketBeat users. However, 74.42% of users gave Immunome an outperform vote while only 73.91% of users gave Edgewise Therapeutics an outperform vote.
In the previous week, Immunome had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 12 mentions for Immunome and 11 mentions for Edgewise Therapeutics. Immunome's average media sentiment score of 0.63 beat Edgewise Therapeutics' score of 0.43 indicating that Immunome is being referred to more favorably in the news media.
Edgewise Therapeutics currently has a consensus target price of $43.17, indicating a potential upside of 61.27%. Immunome has a consensus target price of $28.83, indicating a potential upside of 190.66%. Given Immunome's higher probable upside, analysts plainly believe Immunome is more favorable than Edgewise Therapeutics.
44.6% of Immunome shares are held by institutional investors. 24.1% of Edgewise Therapeutics shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Edgewise Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
Summary
Immunome beats Edgewise Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
This page (NASDAQ:IMNM) was last updated on 1/17/2025 by MarketBeat.com Staff
Free IMNM Stock Alerts